News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

The ribociclib population is more broad ... HER2-negative [HER2–] metastatic breast cancer. They not only improve the PFS, but also improve the overall survival. It's really hard to see any ...

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared to chemotherapy, the ribociclib and letrozole were found to be just as effective and better tolerated.

“We look forward to presenting updated data from our ongoing Phase 2 clinical study of palazestrant in combination with ribociclib in frontline metastatic breast cancer patients at SABCS in December.

Chen cites Ribociclib, a drug used for many years for those with metastatic breast cancer. Recent studies show that it also significantly improves survival among patients with HR-positive ...

Ribociclib, in combination with the aromatase inhibitor letrozole, improves survival in post-menopausal women with hormone receptor-positive metastatic breast cancer. Breast cancer is a cancer ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

(Image Credits: Pexels) The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred ...